Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20539764 | 1.00 | ARG1 (1.00) | ARG1ARG2 | |
| SCHEMBL1739483 | 0.90 | ARG1 (0.85) | ARG1ARG2 | |
| SCHEMBL1742346 | 0.87 | ARG1 (0.77) | ARG1ARG2 | |
| SCHEMBL1741961 | 0.85 | ARG1 (1.00) | ARG1ARG2 | |
| SCHEMBL893919 | 0.85 | ARG1 (1.00) | ARG1ARG2 | |
| SCHEMBL1740826 | 0.85 | ARG1 (1.00) | ARG1ARG2 | |
| SCHEMBL20539750 | 0.83 | ARG1 (1.00) | ARG1ARG2 | |
| SCHEMBL20539751 | 0.83 | ARG1 (1.00) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL894881 | 0.83 | ARG1 (0.96) | ARG1ARG2 | |
| SCHEMBL894341 | 0.83 | ARG1 (1.00) | ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024006841-A2 | COMPOSITIONS FOR WEIGHT LOSS AND CANCER TREATMENT | KNOWLEDGE PHARMACEUTICALS INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20220296584-A1 | Membrane Active Molecules | KNOWLEDGE PHARMACEUTICALS INC. | 2022-09-22 | — | — | US | disclosed |
| EP-3973997-A1 | MEMBRANE ACTIVE MOLECULES | Branequest, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20200375958-A1 | MEMBRANE ACTIVE MOLECULES | KNOWLEDGE PHARMACEUTICALS INC. | 2020-12-03 | — | — | US | disclosed |
| EP-3615084-A1 | MEMBRANE ACTIVE MOLECULES | Branequest, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| WO-2018200412-A1 | MEMBRANE ACTIVE MOLECULES | BraneQuest, Inc. (US) | 2018-11-01 | — | — | WO | disclosed |
| US-20180303821-A1 | MEMBRANE ACTIVE MOLECULES | KNOWLEDGE PHARMACEUTICALS INC. | 2018-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296584-A1 | Membrane Active Molecules | GABRP, GRIN3A, GRIN2A | ARG1 4334/4885ARG2 2061/4885 |
| US-20180303821-A1 | MEMBRANE ACTIVE MOLECULES | GABRP, GRIN3A, GRIN2A | ARG1 4334/4885ARG2 2061/4885 |
| US-20200375958-A1 | MEMBRANE ACTIVE MOLECULES | GABRP, GRIN3A, GRIN2A | ARG1 4334/4885ARG2 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.